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Summary
Each year, over 5 million people die worldwide from
stroke, and at least every sixth patient who survives will ex-
perience another stroke within five years [1]. We are there-
fore eager to advance early and rapid diagnosis, prognosis
and optimal risk stratification, as well as secondary preven-
tion. In this context, blood biomarkers may improve pa-
tient care, as they have already done in other fields in the
past, for example, troponin T/I in patients with heart at-
tacks, natriuretic peptides in patients with heart failure or
PCT (procalcitonin) [2] in patients with pneumonia. In the
setting of acute stroke, a blood biomarker can be any quan-
tifiable entity that reflects the manifestation of a stroke-re-
lated process. The most fruitful implementation of stroke
biomarkers is in areas where information from traditional
clinical sources is limited. There may be markers, for ex-
ample, to guide risk stratification, reveal stroke aetiology,
identify patients who may benefit most from interventions,
monitor treatment efficacy, and recognise the risk of short-
term complications or unfavourable long-term outcomes.
For this review we focus on blood biomarkers that could
help distinguish the underlying aetiology of an ischaemic
stroke. Stroke tends to be a much more heterogeneous con-
dition than ischaemic heart disease, which is caused by
atherosclerosis in the vast majority of cases. Causes of
stroke include small and large vessel disease, cardioem-
bolism, dissections, and rare vasculo- and coagulopathies,
among others. Because of this heterogeneity among stroke
patients, it is clear that a monolithic approach to stroke pre-
vention or secondary prevention is not warranted.
Aetiological classification is important specifically because
prognosis, risk of recurrence and management options dif-
fer greatly between aetiological subtypes. Considering that
today up to 30% of stroke patients still cannot be classified
into a specific subtype [3], the ability to improve aetiolo-
gical classification to direct prevention methods at the un-
derlying mechanism would be of greatest interest.
For this review we collected data from studies, on aeti-
ological blood biomarkers in ischaemic stroke patients, lis-
ted in PubMed up to October 2014. We describe the po-
tential role of 22 selected blood biomarkers in the context
of stroke aetiology. Finally we provide the readers with an
outlook in this research field.
Key words: aetiological blood biomarker; ischaemic
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Introduction
Epidemiology
Stroke is a leading cause of death worldwide. In the United
States of America every year about 795,000 people suffer
Figure 1
Examples of stroke aetiologies (imaging material adapted from
Servier Medical Art).
Figure 2
Most important mechanisms for the formation of cardiac embolism
(imaging material adapted from Servier Medical Art).
PFO = patent foramen ovale
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from a new or recurrent stroke. In Switzerland, stroke in-
cidence has been estimated at 150/100,000 inhabitants [4].
In 2010 direct and indirect costs were $315.4 billion in the
United States of America for cardiovascular disease and
stroke [1, 5].
Stroke can be categorised into ischaemic and haemorrhagic
stroke. Ischaemic stroke accounts for approximately 87%
whereas haemorrhagic stroke accounts for 13% of all
strokes [6].
Ischaemic stroke itself is a heterogeneous disease and dif-
ferent pathological events can lead to a common final
ischaemic cascade within the brain (see fig. 1). In a
European population of incidence stroke, 30.2% were due
to cardioembolism, 25.8% due to small artery/vessel occlu-
sion (SVO) and 15.3% due to large artery atherosclerosis
(LAA). The cause of ischaemic strokes remained undeter-
mined in 25% to 39% of patients even after thorough exam-
ination [7]. Moreover the risk of recurrence differs between
the different etiological subtypes. The highest recurrence
rate was found in cardioembolic strokes (22%), in the same
study the recurrence rate for LAA was 10% [7].
Secondary prevention according to stroke aetiology
In any case of ischaemic stroke it is important to reduce
the overall risk factors that led to the disease with, for ex-
ample, blood-pressure treatment, antidiabetic agents, anti-
platelet therapy and lipid-lowering agents in the case of
atherosclerosis, heart disease or metabolic disorders. There
are some aetiologies where there is, however, a specific
treatment indicated.
If the stroke is due to a cardioembolic event in patients
with atrial fibrillation, it has been shown in several studies
that these patients clearly benefit from oral anticoagulation.
In a first randomised controlled trial – the WARS trial ‒
warfarin was superior to placebo or aspirin in reducing
stroke rates in patients suffering from atrial fibrillation [8,
9]. Over the years, meta-analysis data confirmed that war-
farin reduces the occurrence of stroke in patients with atrial
fibrillation by 64%. After that, several recent studies fol-
lowed, proving a relevant risk reduction of stroke recur-
rence also for novel oral anticoagulants (direct thrombin
inhibitors or factor Xa inhibitors) such as abixaban, dabi-
gatran, rivoroxaban or edoxaban [10–13].
In the case of large vessel disease, if a patient suffers from
a 70% to 99% stenosis without near-occlusion, carotid sur-
gery (carotid endartectomy) showed an absolute risk reduc-
tion of 16% (p <0.001) [14]. Among patients with symp-
tomatic carotid stenosis, the 4-year rate of stroke or death
was clearly reduced to 8.0% with stenting and to 6.4% with
endarterectomy [15]. Overall, the recurrence rate was re-
duced compared with “natural history” rates for both inter-
vention types; however, endarterectomy performed slightly
better than stenting with the exception of some subgroups.
Because of the aetiological heterogeneity and the fact that
prognosis, risk of recurrence and management options dif-
fer greatly between subtypes, it is important to identify rap-
idly and accurately the underlying pathological mechanism
leading to ischaemic stroke.
Aetiological classification systems
Various classifications of ischaemic strokes have been de-
veloped. The TOAST (Trial of Org 10172 in Acute Stroke
Treatment) classification [16] is the most commonly used
classification system. Based on the patient’s neurological
symptoms, imaging of the brain using computed tomo-
graphy or magnet resonance imaging (CT/MRI) and other
diagnostic tests, including standard 24-hour electrocardio-
graphy (ECG), echocardiography and ultrasound of extra-
and intracranial arteries, the most likely aetiology is de-
termined.
The TOAST classification divides ischaemic strokes into
the following subtypes:
Ischaemic stroke due to large artery atherosclerosis, cardi-
oembolism, small vessel occlusion, ischaemic stroke of un-
determined aetiology and ischaemic stroke of other determ-
ined aetiology [16].
Currently, at least two newer sub-classification systems,
the SSS-TOAST [17] and the A-S-C-O classification [18],
are available. These newly developed classification sys-
tems are advancing the accuracy of ischaemic stroke sub-
type diagnosis by taking into account the level of dia-
gnostic evidence in order to devise the “most likely mech-
anism” in the presence of multiple potential overlapping
causes (i.e. SSS-TOAST classification) or the “phenotype”,
which categorises stroke patients according to a combina-
tion of their aetiological characteristics (ASCO). These ad-
vanced systems, however, are not yet widely used in clin-
ical routine, they are more complex (though more precise)
and so far no data have been published on their impact on
implementation of secondary prevention and clinical man-
agement in clinical routine.
Recently, a new approach [19] was suggested by scientists
to how the former group of “cryptogenic strokes” should
be defined and treated. Originally, patients were categor-
ised as having “cryptogenic strokes”, a subgroup within the
“undetermined” group according to the TOAST criteria, if
even after extensive evaluation no aetiology was determ-
ined. They proposed that most of these types of stroke are
of an embolic nature, they called this embolic stroke of un-
determined source (ESUS). Per definition an ESUS has to
be a nonlacunar brain infarction without a proximal arteri-
al stenosis or a major-risk cardioembolic source that would
present a clear indication for anticoagulation. They further-
more recommended anticoagulation therapy in these pa-
tients and currently there are several trials ongoing, which
aim to prove that these patients might benefit from the nov-
el anticoagulants.
Pathophysiology of ischaemic strokes
Ischaemic stroke due to large artery atherosclerosis
In the initial phase of atherosclerosis the endothelium is
injured. This leads to a dysfunctional endothelium. More
and more low density lipoproteins (LDLs) are deposited
in the intima part of the artery. The accumulation of LDL
induces endothelial cells to produce chemokines. These
chemokines (e.g. monocyte chemotactic protein-1
[MCP-1]) attract monocytes and change them into macro-
phages. The macrophages enter into the intimal part of the
vessel. Endothelial cells and macrophages oxidise LDL.
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Macrophages which take up oxidised LDL then turn into
foam cells. The foam cells increase in size, unable to meta-
bolise the lipoproteins, and finally die. This in turn leads to
inflammation of the lipid plaques. The inflammatory reac-
tion finally leads to destabilisation of the plaque and poten-
tially to plaque rupture, inducing an occlusion of the blood
vessel further upstream, and consequently to ischaemia of
brain tissue [20]. Moreover the diameter of the atheroscler-
otic vessel locally decreases and this stenosis can then lead
to hypoperfusion of the upstream cerebrovascular tissue.
According to the TOAST classification, an ischaemic
stroke is due to large artery atherosclerosis if either a major
brain supplying artery or major cortical artery shows a
>50% stenosis or occlusion and the infarction is located in
the corresponding vessel territory. Other competing reas-
ons have to be unlikely. These pathological changes (>50%
stenosis) in an intra- or extracranial artery has to be clearly
shown by ultrasound or imaging to consolidate the dia-
gnosis of ischaemic stroke due to large artery atherosclero-
sis [16].
The beginning of the pathophysiological process in
ischaemic strokes due to large artery atherosclerosis is of
an inflammatory nature. As a consequence, blood biomark-
ers indicating inflammatory processes in vessels might be
promising aetiological biomarker candidates.
Ischaemic stroke due to cardioembolism
Virchow’s triad, including hypercoagulability, endothelial
injury and stasis of blood flow, is commonly known to lead
to blood clotting. Prothrombin is activated by tissue factors
and then changed into thrombin. Thrombin cuts fibrinogen
into fibrin. The fibrin molecules react with each other and
build cross-linked fibrin. Cross-linked fibrin then interacts
with thrombocytes, which themselves adhere to the fibrin,
building a thrombus. A thrombus moved by blood flow is
called an embolus. In ischaemic stroke due to cardioembol-
ism, the source of the ischaemic event is an embolic occlu-
sion of a brain vessel and the origin of the embolus is loc-
ated in the vicinity of the heart.
There are mainly three mechanisms of embolism coming
from the heart (fig. 2):
1. local haemostasis in a cardiac chamber which leads to
thrombosis (e.g. left atrial septal aneurysm and left
ventricular aneurysm or, most important, atrial
fibrillation);
2. material released from an abnormal cardiac surface (e.g.
calcific degeneration);
3. abnormal passage between the venous and arterial
system in the heart which allows venous material to
end up in the arterial circulation (e.g. patent foramen
ovale).
Major sources for cardioembolism are atrial fibrillation,
mitral stenosis, prosthetic valves, infective endocarditis,
marantic endocarditis, atrial myxoma, acute myocardial in-
farction, left ventricular thrombosis, left ventricular an-
eurysm and left ventricular failure. Minor sources are pat-
ent foramen ovale, atrial septal aneurysm, atrial or
ventricular septal defects, calcific aortic stenosis, mitral an-
nular calcification and fibroelastoma [21]. In the case of
atrial fibrillation ‒ the most common source of cardioem-
bolism – supraventricular tachyarrhythmia causes unco-
ordinated muscle contractions leading to a sluggish blood
flow in the atrium, with the consequence that coagulation
thrombi are produced, consisting of mostly fibrin and plate-
lets [22].
Ischaemic stroke due to cardioembolism usually comes
with greater mortality and morbidity because of the occlu-
sion of mainly large intracranial arteries [22]. Moreover the
highest recurrent rate in ischaemic stroke among all sub-
groups is found in cardioembolism [7].
According to the TOAST criteria a cardiac source of em-
bolism must be detected to verify whether it is an ischaemic
stroke due to cardioembolism. In case there are no such
findings, clinical signs and imaging of the patient are very
similar to those patients suffering from large artery ather-
osclerosis. In that peculiar case blood biomarker may add
important information to better identify a cardioembolic
source.
Ischaemic stroke due to small vessel disease / small vessel
occlusion
Ischaemic stroke due to small vessel disease (SVD) is
mainly due to arteriosclerotic SVD and sporadic and hered-
itary cerebral amyloid angiopathy [23].
Arteriosclerotic SVD can be attributed to several
pathomechanisms: fibrinoid necrosis, lipohyalinosis, mi-
croatheroma, microaneurysms and segmental arterial disor-
ganisation.
In the case of arteriosclerosis as the cause of small vessel
disease, the number of smooth muscle cells in the tunica
media is reduced, the blood vessel wall thickens through
deposition of fibro-hyaline material and consequently the
vessel lumen decreases, leading to an undersupply to the
surrounding cerebrovascular tissue. Arteriosclerotic SVD
is most often associated with systemic hypertension [23].
In sporadic and hereditary cerebral amyloid angiopathy, a
progressive accumulation of βA4 immunoreactive amyloid
proteins in the wall of small and medium arteries and ar-
terioles can lead to occlusion of the vessel [23].
The most important risk factors for a small vessel stroke
are hypertension, diabetes and smoking [24]. According to
the TOAST criteria, a stroke is due to small vessel disease,
if a cardioembolic source has been excluded and the ab-
sence of a carotid or vertebral stenosis of >50% of the ves-
sel diameter has been shown. Occlusion of small vessels
causes small infarcts, termed lacunes, most commonly loc-
ated in the caudate, putamen, external capsule, internal cap-
sule, corona radiata, pontine tegmentum and thalamus. Fur-
thermore, the diameter of the typical subcortical infarction
has to be ≤1.5 cm in diameter [16].
Ischaemic stroke due to “other” determined origins
There are several rather rare diseases, which also lead
through distinct mechanisms to cerebral ischaemia (table
1). According to the TOAST criteria, they belong to the
huge subgroup classified as “other determined aetiologies”.
According to the TOAST criteria [16], patients suffering
from an ischaemic stroke in this subgroup should have a
CT or MRI imaging finding of ischaemic stroke, further-
more the specific cause of the stroke should be revealed by
blood tests or arteriography, and cardioembolism or large
artery atherosclerosis should be excluded by diagnostic
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testing. The ischaemic stroke can be of any size and at any
location in the brain.
Some examples of this category are strokes due to systemic
vasculitis as it is, for example, the case in patients with
lupus erythematosus, other causes are cervical artery dis-
sections or some underlying haematological disorders.
Since this aetiological subgroup contains a plethora of dif-
ferent diseases, including some very rare causes, we
provide the reader with only an overview of some import-
ant exponents:
Undetermined ischaemic stroke
Unfortunately, the aetiology of ischaemic stroke remains
undetermined in up to 25–39% of patients [3], thus up to at
least ¼ of ischaemic stroke patients lack potential adequate
secondary prevention treatment.
According to the TOAST criteria the following patient
groups are classified as such when even after extensive
evaluation no aetiology is determined (cryptogenic) or the
cause has not been found because the evaluation was only
cursory or the physician determined two or more possible
causes, making a final diagnosis impossible [16].
If we could reduce the proportion of undetermined strokes
with the help of biomarkers, recurrence rate might be re-
duced substantially.
Common final ischaemic cascade
The final common pathway of all ischaemic strokes is the
obstruction of arterial flow to the brain. Brain tissue de-
pends on a constant supply of oxygen and glucose. In
the case of ischaemic stroke this supply is decreased or
even abolished. The impact on neurones depends on the
size, location and duration of the ischaemia. After 5 to 10
minutes of local depletion of glucose and oxygen, neur-
ones are harmed irreversibly. The inadequate supply of en-
ergy can lead to a deterioration of the ion gradient. The
neuronal and non-neuronal cells depolarise. Thereby the
brain cell loses potassium in exchange for sodium, chloride
and calcium ions. This electrolyte imbalance leads to a
water inflow into the cell and results in rapid swelling
of the neurones and glia cells ‒ cytotoxic oedema. The
harmed cell now releases excitatory neurotransmitters such
as glutamate. Glutamate interacts with several cell mem-
brane proteins and, as a result of excessive cell depolar-
isation, many enzymes are activated, which now release
oxygen free radicals. These oxygen free radicals react with
intra- and extracellular proteins and thereby finally lead
to cell necrosis. Oxygen free radicals may even induce
programed cell death (apoptosis) in damaged cells [25].
Aetiological blood biomarkers
Definition of aetiological blood biomarkers
Aetiological blood biomarkers are associated with
physiological or pathophysiological processes in the hu-
man body leading to an ischaemic stroke. Ideally, they
should be reliable and simple to measure; they should help
scientists to gather further meaningful information about
the aetiology of ischaemic stroke. Specifically, they should
improve the identification of patients who need specific
secondary preventive treatment and thereby allow faster
initiation of treatments, ultimately leading to a better out-
come.
Literature search for aetiological blood biomarkers
The markers we describe in the following paragraphs were
identified by a PubMed search. We collected data from
studies, written in English, on aetiological blood biomark-
ers in ischaemic stroke patients, listed in PubMed up to
October 2014. Search terms were: stroke / ischaemic
stroke, cerebrovascular disease, etiology/aetiology, blood
biomarker / biomarker. Among a total of 1,268
manuscripts, we selected 117 possible relevant papers ac-
cording to their heading in the title. The title of the paper
had to be a relevant hint to our paper topic. After reading
the abstracts of these 117 papers, we finally selected 31
manuscripts with detailed information about blood bio-
markers and their significant association with a specific
ischaemic stroke aetiology compared with other aetiolo-
gies. We then categorised the biomarkers by each aetiology
according to the TOAST classification system. Since the
field of biomarkers in the setting of stroke aetiology is
rather a new site of interest for scientists, so far there are
only a few reviews on this topic. Currently, an interesting,
comprehensive review has been published in this field [26].
Large artery atherosclerosis (LAA) biomarkers
Table 2 summarises the characteristics of the following ae-
tiological blood biomarkers of LAA strokes.
Table 1: Examples of “Other determined ischaemic strokes”. Adapted from Handbook of Clinical Neurology, Volume 93, Pages 1–982 (2008) Stroke Part II: Clinical
Manifestations and Pathogenesis, Edited by Marc Fisher (ISBN: 978–0–444–52004–3).
Haematological disease: Vasculitis and vasculopathies: Cervical artery dissection
– Protein C, S, Z deficiencies – Giant cell arteriitis / polymyalgia rheumatica – Idiopathic
– Factor V Leiden mutation – Kawasaki syndrome – Traumatic
– Plasminogen deficiency –Takayasu’s arteritis – Marfan’s syndrom
– Essential thrombocythaemia – Polyarteritis nodosa – Fibromuscular dysplasia
– Von Willebrand’s disease – Lupus erythematosus – Ehlers-Danlos syndrome
– Antiphospholipid syndrome – Isolated central nervous system angiitis
– Behçet disease
Infections: Drug Abuse:
– Human immunodeficiency virus, varicella zoster virus – Cocaine
– Lyme disease – Amphetamine
– Syphilis – Ephedrine
– Infective endocarditis – Phenylpropanolamine
– Malaria
Review article: Current opinion Swiss Med Wkly. 2015;145:w14138
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Decorin
Decorin is a matrix proteoglycan. It is a component of con-
nective tissue. Decorin binds to type 1 collagen fibrils and
is involved in matrix assembly. It is associated with the
ability to modify plaque phenotype by reducing inflam-
mation. Decorin reduced the activity of macrophages, the
activity of gelatinase and the collagen plaque content in a
mouse model [27].
In a small case control study [28], decorin levels in patients
with ischaemic stroke (n = 35) were lower compared with
healthy controls (n = 30). Moreover, among stroke patients
decorin levels were about 1.3 lower in large artery ather-
osclerosis (n = 23) (average: approximately 7,200 pg/ml),
than in other ischaemic stroke subtypes (n = 12) (average:
approximately 9,200 pg/ml) when measured <3 days after
symptom onset.
CD62P / P Selectin
Cluster of differentiation (CD) 62P, or P selectin as it is
called, is a cell adhesion protein found on blood vessel en-
dothelium and on activated platelets. It plays a role in the
initial recruitment of leucocytes in an inflammatory pro-
cess such as atherosclerosis.
In a case control study [29], the percentage of platelets
expressing CD62P in patients with ischaemic stroke of
Table 2: Aetiological blood biomarkers of large artery atherosclerosis (LAA) strokes.
Blood
biomarker
LAA marker
Description Potential clinical application Study reference Size Study design
Decorin Matrix proteoglycan, component of connective
tissue, binds to type I collagen fibrils and is
involved in matrix assembly (cell cycle)
Diagnosis of LAA in acute
ischaemic stroke
Xu et al. 2012 [28] 65 patients, 23 LAA Case control
study
CD62P P-selectin, stimulated by thrombin, recruitment of
leucocytes in inflammation, binding of
thrombocytes
Diagnosis of LAA in acute
ischaemic stroke
Tsai et al. 2009 [29] 54 patients, 22 LAA Case control
study
CD63 Cell surface protein, involved in adhesion of blood
cells to endothelial cells
Diagnosis of LAA in acute
ischaemic stroke
Tsai et al. 2009 [29] 54 patients, 22 LAA Cohort study
CXCL16 Scavenger receptor and chemokine, involved in
oxLDL uptake in monocytes, enhances
atheriosclerosis
Diagnosis of LAA in acute
ischaemic stroke
Ma et al. 2014 [37] 227 patients, 86 LAA Cohort study
Katan et al. 2014 [40] 1,946 patients,
381 LAA
Cohort studyLP PLA2 Platelet activating factor, increases inflammatory
reaction
Diagnosis of LAA in acute
ischaemic stroke
Delgado et al. 2012 [41] 166 TIA patients,
38 LAA
Cohort study
LIGHT Tumour necrosis factor ligand, proinflammatory
prothrombotic effects on tissue, induces
atherosclerosis
Differentiation of LAA in acute
stroke compared with healthy
controls
Liu et al. 2008 [43] 62 patients, 20 LAA Case control
study
Oberheiden et al. 2012
[32]
51 patients, 11 LAA Cohort studysCD40L Binds CD40 on APCs, promotes inflammatory
action on endothelial cells
Differentiation of vessel disease
from CE origin
Wang et al. 2013 [31] 119 patients, 30 LAA Cohort study
Total serum
cholesterol
Hydrophobic sterol molecule, found in cell
membranes, induces atherosclerosis?
Diagnosis of LAA in men in
acute ischaemic stroke
Cui et al. 2012 [44] 33,469 patients, 612
ischaemic stroke,
107 LAA
Cohort study
Serum
lipoprotein A
Lipoprotein, involved in atherosclerosis Diagnosis of LAA in ischaemic
stroke
Kim et al. 2010 [45] 1,012 patients,
281 LAA
Cohort study
Adiponectin Adipocytokine of adipose tissue, reduction of
atherosclerotic development, improve insulin
resistance
Diagnosis of LAA in acute
ischaemic stroke
Kuwashiro et al. 2014
[49]
342 patients, 34 LAA Cohort study
Zeng et al. 2013 [46] 99 patients with
noncardioembolic
stroke, 52 LAA
Cohort studyC-reactive
protein
Inflammatory marker Diagnosis of LAA in
noncardioembolic ischaemic
stroke
Ladenvall et al. 2006
[47]
1,200 patients, 73 LAA Cohort study
APC = antigen presenting cell; CD = cluster of differentiation; CXCL16 = C-C-C motif chemokinreceptor 16; LIGHT = lymphotoxin-like inducible protein that competes with
glycoprotein D for binding herpesvirus entry mediator on T lymphocytes; LP PLA2 = lipoprotein-associated phospholipase A2; oxLDL = oxidised low density lipoprotein; TIA
= transient ischaemic attack
Table 3: Table of BNP/NTproBNP studies.
Author Biomarker Cut-off (pg/ml) AUC Sensitivity (%) Specificty (%)
Tamura et al. 2012 [54] BNP 90 0.892 85 78
Montaner et al. 2008 [55] BNP 76 0.75 72 68
Zhixin et al. 2013 [58] BNP 55.50 0.896 75 88.7
Yukiiri et al. 2008 [59] BNP 77 0.763 75.8 76.8
Shibazaki et al. 2009 [57] BNP 140.0 0.87 80.5 80.5
Fonseca et al. 2011 [61] NTproBNP 265 0.92 94.4 72.9
Hajsadeghi et al. 2013 [62] NTproBNP 342 0.882 93 75
Rodriguez-Yanez et al. 2009 [63] NTproBNP 360 0.921 87 83
AUC = area under the concentration-time curve; BNP = brain natriuretic peptide; NTproBNP = N-terminal probrain natriuretic peptide
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noncardioembolic origin (n = 54, median percentage of
platelets expressing P selectin: 5.4%) were compared with
healthy controls (n = 28, median number of platelets ex-
pressing P selectin: 3.77%). They then compared patients
with ischaemic stroke due to large artery atherosclerosis
with patients suffering from ischaemic stroke due to small
vessel disease. P selectin was measured at three different
time-points (<48 h, 7 d, 30 d, 90 d after symptom onset).
The percentage of circulating platelets expressing P se-
lectin was increased two-fold (p <0.05) from onset to 3
months after the event in patients with ischaemic stroke
due to large artery atherosclerosis (n = 22, median percent-
age of platelets expressing P selectin: 9.9%) compared with
ischaemic stroke due to small vessel disease (n = 32, medi-
an percentage of platelets expressing P selectin: 4,9%).
CD63
CD63 (cluster of differentiation 63) is a cell surface gly-
coprotein and marker. CD63 levels are elevated in inflam-
matory processes. To enable platelets to aggregate, they
have to be activated thus CD63 might contribute to athero-
thrombosis and atherothrombotic stroke [30].
In a small case control study [29] CD63 levels in patients
with acute ischaemic stroke of noncardioembolic origin
(n = 54, median percentage of platelets expressing CD63:
2.33%) and healthy controls (n = 28, median percentage of
platelets expressing CD63: 1.15%) were measured. CD63
levels were 1.52 times higher (p <0.05) in patients with
acute ischaemic stroke due to large artery atherosclerosis
(n = 22, median percentage of platelets expressing CD63:
3.2%) than in cases due to small vessel disease (n = 32,
median percentage of platelets expressing CD63: 2.1%) if
measured 48 hours after symptom onset. Afterwards (7, 30
and 90 d after symptom onset) there was no significant dif-
ference detectable.
Soluble CD40L (cluster of differentiation 40 ligand)
The soluble CD40 ligand belongs to the tumour necrosis
factor superfamily (TNFSF) family. It binds to the CD40
receptor on antigen-presenting cells. It promotes inflam-
matory activation on endothelial cells [31]. Thus it is prom-
inently involved in vessel inflammation [30].
In a small cohort study [32] levels of soluble CD40L were
significantly higher in patients with large artery athero-
sclerotic stroke (n = 11, 165.01 ± 73.76 pg/ml; p <0.047)
compared with patients suffering from stroke of cardioem-
bolic origin (n = 17, 75.33 ± 30.72 pg/ml), but levels
did not differ significantly between patients suffering from
stroke due to large artery atherosclerosis and patients suf-
fering from stroke due to small vessel disease (n = 13).
In another small study [31], scientists compared ischaemic
stroke patients (n = 82) with normal healthy individuals (n
= 20) and patients who had carotid artery stenosis without
stroke (n = 17). Soluble CD40L levels were higher in pa-
tients suffering from stroke either because of large artery
atherosclerosis (8.41 ± 2.89 ng/ml) or small vessel disease
(7.41 ± 3.49 ng/ml), compared with healthy controls (0.56
± 0.40 ng/ml) and compared with patients with carotid
stenosis without stroke (3.71 ± 1.19 ng/ml). In the same
study, the mean fluorescence intensity of CD40L expres-
sion on peripheral blood monocytes was significantly high-
er in patients suffering from large artery atherosclerosis
(26.87 ± 9.43) compared with all other subgroups (normal
controls 7.65 ± 2.64, carotid artery stenosis 14.59 ± 2.18,
small vessel disease 7.08 ± 3.09, cardioembolism 7.94 ±
2.46).
CXCL16
CXCL16 (C-C-C motif chemokinreceptor 16), also known
as SR-PSOX (scavenger receptor that binds phos-
phatidylserine and oxidised lipoprotein), is a chemokine
and works as a scavenger receptor [33, 34]. In atheroscler-
otic plaques high levels of CXCL16 were found. It is seen
to be involved in the uptake of oxidised low-density lipo-
protein (LDL) in monocytes and thereby enhancing athero-
sclerosis [33, 35, 36].
In a small cohort study [37], scientists compared CXCL16
levels in patients who suffered from ischaemic stroke due
to LAA (n = 86) or SVD (n = 67) and healthy controls (n
= 74). Mean CXCL16 levels were higher in SVD (c = 2.13
ng/ml, p <0.05) and LAA (c = 2.36 ng/ml, p <0.01) strokes
compared to healthy controls(c = 2.04 ng/ml).
When mean CXCL16 levels in LAA and SVD strokes were
compared, mean CXCL16 levels were 1.1 times higher in
patients suffering from LAA stroke compared with SVD
strokes (p <0.05).
LP PLA2
Lipoprotein-associated phospholipase A2 (LP PLA2) is an
enzyme produced by inflammatory cells. It plays an im-
portant role in the development of atherosclerosis. LP
PLA2 hydrolyses oxidised phospholipids, thus producing
lysophosphatidylcholine and oxidised nonesterified fatty
acids (OxNEFA). OxNEFA have chemotactic activity to-
wards monocytes and lysophoshatidylcholine is able to up-
regulate inflammatory mediators and thereby enhance the
process of evolving atherosclerosis [38].
In a cohort study [39] higher levels of LP PLA2 were asso-
ciated with carotid stenosis (n = 19) as compared with pa-
tients with ischaemic stroke without showing carotid sten-
osis (n =111) and healthy controls (n = 20).
In a large cohort study [40] (n = 1,946) LP PLA2 was found
to be associated with ischaemic stroke due to large artery
atherosclerosis in white non-Hispanic men (n = 381, hazard
ratio 3.05). This association remained even after adjusting
for confounders.
In another study [41], scientists compared patients suffer-
ing from transient ischaemic attack (TIA) with healthy con-
trols. Patients suffering from TIA due to large artery ather-
osclerosis had higher LP PLA2 activity (207 nmol/ml/min)
compared with patients suffering from TIA due to non-
large artery atherosclerosis (184 nmol/ml/min, p = 0.044).
LIGHT
The lymphotoxin-like inducible protein that competes with
glycoprotein D for binding herpesvirus entry mediator on T
lymphocytes (LIGHT) is a member of the TNFSF, the tu-
mour necrosis factor super family. LIGHT has proinflam-
matory and prothrombotic effects. It is an inducer of matrix
metalloproteinase (MMP) in macrophages and is involved
in platelet adhesion to endothelium. When macrophages
are costimulated with oxLDL (oxidised low density lipo-
proteins) and LIGHT at the same time, the macrophage sig-
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nificantly increases the uptake of neutral lipids (≈20% in-
crease) which results in quicker building of foam cells [42]
and thus atherosclerosis.
In a small case control study [43] scientists compared
levels of LIGHT in patients suffering from atherosclerotic
ischaemic stroke (n = 20) to patients with asymptomatic ca-
rotid stenosis (stenosis >50%, n = 19) and healthy controls
(n = 23).LIGHT levels were 4.1 times higher in patients
suffering from ischaemic stroke due to large artery ather-
osclerosis (LIGHT: 350 pg/ml, p <0.05) than in normal
healthy patients (LIGHT: 85 pg/ml, p <0.05), but LIGHT
levels were not significantly different compared with pa-
tients with asymptomatic carotid stenosis.
High serum total cholesterol
Cholesterol is a hydrophobic sterol molecule. It is the base
substance of cell membranes and of many hormones. Par-
ticularly high levels of cholesterol in the blood circulation,
depending on how they are transported within lipoproteins,
are strongly associated with the progression of atheroscler-
osis.
In a large Japanese cohort study with 612 ischaemic stroke
patients, scientists found out that high serum total choles-
terol levels in Japanese men (>6.21 mmol/l) were associ-
ated with large artery atherosclerosis (multivariable hazard
ratio 2.86). They did not find such differences for ischaem-
ic stroke due to large artery atherosclerosis in Japanese wo-
men [44].
Serum lipoprotein A
Serum lipoprotein A is a lipoprotein consisting of apoli-
poprotein A and apolipoprotein B-100. It belongs to the
group of LDL (low density lipoprotein). Serum lipoprotein
A might be involved in the process of atherosclerosis.
In a large cohort study [45], serum lipoprotein A levels
were measured in patients suffering from ischaemic stroke
or TIA (n = 1,012). Highest levels of serum lipoprotein A
were found in patients suffering from LAA (n= 281, medi-
an c = 34.6 mg/dl) (CE: n = 204, median c = 29.2 mg/dl,
SVD: n = 261, median c = 24.2 mg/dl, other determined: n
= 74, median c = 24.1, undetermined: n = 192, median c =
27 mg/dl)
C-reactive protein
C-reactive protein (CRP) is an acute-phase protein pro-
duced in the liver. CRP is an inflammation marker. It is part
of the innate immune response, and it is capable of sever-
al immunological actions that may contribute to the chron-
ic inflammatory process that constitutes atherosclerosis. In
the acute phase, the systemic immune-inflammatory reac-
tion is more enhanced in cardioembolic stroke then in other
stroke subtypes, which makes CRP an ambivalent marker
for strokes.
In a small study [46], scientists examined levels of CRP in
noncardioembolic ischaemic strokes (n = 99). They stud-
ied the differences in CRP levels between patients suffering
from ischaemic stroke due to large artery atherosclerosis (n
= 52) and patients suffering from small vessel disease (n =
47). When CRP levels were measured on the day of onset,
levels were 1.85 times higher in LAA patients compared
with SVD patients (p <0.05) [46].
In another study [47], CRP levels were measured in
ischaemic stroke patients (n = 600) and healthy controls (n
= 600) at two different time-points, at acute phase and after
3 months. Highest levels of CRP were measured in cardi-
oembolic strokes (n = 98) when measured at acute phase
(1.5 times higher in cardioembolism than in LAA strokes)
but after a 3-month follow-up the highest levels of CRP
were found in the subgroup of LAA (n = 73) (1.3 times
higher in LAA than in cardioembolic strokes).
Adiponectin
Adiponectin is secreted by the adipose tissue. It is involved
in lipid and glucose metabolism, it stimulates glucose up-
take and metabolism in muscle cells and decreases glucose
production in the liver, and it is involved in energy homeo-
stasis. Adioponectin improves the insulin resistance level
of the tissue. Adiponectin might play a protective role in
case of atherosclerosis [48].
In a small study [49], adiponectin levels were 0.53 times
lower in patients suffering from LAA stroke (n = 34, 2.7
± 0.5 µg/ml, p = 0.047) compared with patients suffering
from cardioembolic stroke (n = 49, 5.3 ± 0.5 µg/ml). Adi-
ponectin levels were also 0.71 times lower in LAA strokes
compared with healthy control patients (n = 171, 3.8 ± 0.2
µg/ml).
Cardioembolic biomarkers
Brain natriuretic peptide
Brain natriuretic peptide (BNP) is a vasoactive peptide hor-
mone, produced in heart and brain tissue. Its function is of a
natriuretic and diuretic nature. BNP is mostly secreted from
myocardium in response to increased intracardiac pressure
or increased wall tension [50–53]. Thus it represents un-
derlying cardiac disease, which might be associated with
thrombus formation.
Several studies [54–59] have showed that high BNP levels
in blood are associated with strokes of cardioembolic ori-
gin.
In a cohort study with 223 ischaemic stroke patients, a BNP
cut off level of 90 pg/ml had a sensitivity 85% and a spe-
cificity of 78% to identify a cardioembolic origin, blood
samples were taken >7 days after symptom onset (cardi-
oembolic stroke: n = 69).
When blood samples were taken within 24 hours after
symptom onset in another cohort study (n = 707), a BNP
cut-off of 76 pg/ml identified a cardioembolic stroke with a
specificity of 68% and a sensitivity of 72% (cardioembolic
stroke: n = 259).
In a further independent cohort of 362 ischaemic stroke pa-
tients, those suffering from cardioembolism (n = 144) had
the highest median BNP levels (n = 144, 179.5 pg/ml) com-
pared with the median level in other subtypes (57.2 pg/ml)
(undetermined n = 144, LAA n = 76, SVD n = 61, other n
= 16).
Similar results were found in a study [58] with 142
ischaemic stroke patients. In this study it was possible
to distinguish cardioembolicfrom noncardioembolic stroke
with a cut-off value of 66.50 pg/ml, with a sensitivity of
75.0% and a specificity of 88.7%.
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Finally, in a recent small cohort study [59] scientists com-
pared BNP levels among aetiological subtypes in ischaem-
ic stroke patients (n = 131). Patients suffering from cardi-
oembolism could be identified with a cut-off BNP value of
77 pg/ml, with a sensitivity of 75.8% and a specificity of
76.8%, compared with all other aetiologies.
N-terminal probrain natriuretic peptide
N-terminal probrain natriuretic peptide (NTproBNP) is a
stable fragment of the precursor hormone of BNP. This pre-
cursor molecule is divided into two parts. It follows that
NTproBNP is produced in an equimolar amount to BNP,
but it is more stable, which might be an advantage over
BNP as blood biomarker.
In a cohort study of 163 ischaemic stroke patients [60], the
highest NTproBNP levels were found in CE stroke patients
(mean levels 917.4 ± 82.8 pmol/l, p <0.001, n = 82) com-
pared with other subtypes. (Mean level in ischaemic stroke
subtypes: LAA: 717.2 ± 66.6 pmol/l p <0.001, n = 37):
SVD: 696.6 ± 67.4 pmol/l, p <0.001; n = 22; other determ-
ined: 683.4 ± 69.4 pmol/l, p <0.001, n = 22.)
In a relatively small study [61] (n = 93 patients, 66 with
ischaemic stroke [28 due to cardioembolism]) NTproBNP
levels were 3.9 times (p <0.001) higher in patients suffering
from ischaemic stroke due to cardioembolism (491.6 pg/
ml) than noncardioembolic ischaemic stroke (124.7 pg/ml)
when measured <72 hours after symptom onset. In this
study the cut-off value was 265 pg/ml NTproBNP. It was
possible to distinguish cardioembolism from other sub-
types with a sensitivity of 94.4%, a specificity of 72.9%,
and a positive predictive value of 56.6% and a negative
predictive value of 97.2%. Interestingly, NTproBNP levels
were not associated with the size of stroke.
In a slightly larger cohort study [62] (n = 125 patients,
57 patients with stroke of cardioembolic origin), a NT-
proBNP level ≥342 pg/ml, was associated with a cardioem-
bolic stroke with a sensitivity of 93% and a specifity of
75%.
In another study [63] scientists tried to indentify the cause
of ischaemic strokes in patients with cryptogenic ischaemic
stroke. Among patients with cryptogenic strokes NT-
proBNP levels above 360 pg/mL were attributed to an un-
derlying cardioembolic source of the stoke with a sensitiv-
ity of 87% and a specificity of 83%.
BNP and NTproBNP seem to be quite reliable markers for
cardioembolism in ischaemic stroke, measured early after
stroke onset. All studies showed that BNP or NTproBNP
levels in ischaemic stroke of cardioembolic origin are sig-
nificantly higher than in ischaemic stroke due of noncardi-
oembolic origin. Ten studies were found showing that BNP
and NTproBNP are able to distinguish accurately a cardi-
oembolic stroke from other subtypes. However no direct
comparison between BNP and NTproBNP were made, and
thus so far we are not able to state which marker might per-
form better.
A list of the above mentioned studies which contain cut-
off values and AUC (area under the curve) (eight out of ten
studies) for either BNP or NTproBNP is presented in table
3:
Midregional proatrial natriuretic peptide
Midregional proatrial natriuretic peptide (MRproANP) is a
stable fragment of the precursor hormone of ANP. It is pro-
duced in an equimolar amount to ANP. ANP has a natriur-
etic, diuretic and vasodilating function and thereby is able
to regulate blood pressure. It is mainly produced by car-
diomyocytes of the atrium and secreted during increased
atrial wall tension [64, 65]. The midregional fragment of
proANP is more stable than the N- or C-terminal part of the
precursor in vivo and in blood ex vivo, which might render
it generally more applicable to clinical practice then other
fragments of natriuretic peptides [66].
In a prospective observational study [67], MRproANP
levels were 1.66 times higher (p <0.0001) in patients with
ischaemic stroke due to cardioemolism (n = 131, 206 pmol/
l) compared with patients with noncardioembolic strokes
(n = 228, 124 pmol/l). If MRproANP levels were >180
pg/ml the ischaemic stroke was most probably due to car-
dioembolism (specificity 60.3%, sensitivity 71%, positive
likelihood ratio 2.0, negative likelihood ratio 0.6). This as-
sociation was independent of known risk factors for cardi-
oembolic strokes such as known atrial fibrillation or con-
gestive heart failure.
D-dimer
D-dimer is a fraction of fibrin, produced when plasmin is
activated. It is a marker of haemostatic imbalance. D-di-
mers are a product of the degradation of fibrin by plasmin,
thus they are involved in thrombus formation. In cases of
ischaemic stroke due to cardioembolism, thrombi mainly
consist of fibrin and platelets [22]. It follows that the de-
gradation of the thrombus is associated with a higher sys-
temic D-dimer concentration.
Several studies [55, 68, 69] showed that D-dimer levels are
significantly higher in ischaemic strokes of cardioembolic
origin than in those of noncardioembolic origin.
In a relatively small cohort study [68] (patients n = 98, pa-
tients with ischaemic stroke of cardioembolic origin n =
53), D-dimer levels were 1.9 times higher in cardioembolic
strokes compared with other subtypes of stroke. When D-
dimers were measured within 6 hours after symptom onset,
a level below 300 µg/l ruled out a stroke due to cardioem-
bolism (sensitivity 100%, specificy 53%).
Another study [55] with a similar result compared cardi-
oembolic (n = 259; mean value 1.1 µg/ml, p <0.01) to
noncardioembolic ischaemic strokes (n = 448; LAA mean
value 0.5 µg/ml, SMV mean value 0.6 µg/ml, Undetermin-
ed stroke: mean value 0.8 µg/ml). When the D-Dimer level
was >0.96 µg/ml (960 µg/l) the corresponding OR was 2.2
for cardioembolism compared to large artery atherosclero-
sis.
In a further cohort study [69], mean D-dimer levels were
1.7 times higher in patients suffering from cardioembolic
ischaemic stroke (1,287.50 ng/ml, n = 34) than patients suf-
fering from noncardioembolic stroke (750.20 ng/ml, n =
42).
Soluble thrombomodulin
Soluble thrombomodulin (sTM), or CD141 antigen as it is
called, is an endothelial-specific type 1 membrane recept-
or. When bound to thrombin protein C is activated. Protein
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C degrades clotting factors Va and VIIIa and this leads to
a reduction of coagulation [70]. After an ischaemic stroke
soluble thrombomodulin is most likely upregulated to bal-
ance blood clotting homeostasis
In a small cohort study [71], scientists investigated soluble
thrombomodulin levels in patients suffering from ischaem-
ic stroke (n = 93). Mean levels of sTM were highest (3.79 ±
1.26 ng/ml) in patients suffering from ischaemic stroke due
to cardioembolism and lower in the LAA subgroup (2.38 ±
0.68 ng/ml, p <0.009) as well as in the SVD group (2.38 ±
0.44 ng/ml, p <0.05).
tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6)
and interleukin-1beta (IL-1β)
All of these three molecules are inflammatory markers. In-
flammation plays a role in thrombus formation or degrad-
ation. An alternative association with cardioembolic stroke
might be explained by the fact that the systemic immune-
inflammatory reaction is more pronounced in cardioembol-
ic stroke then in other stroke subtypes.
In a small study [72] (ischaemic stroke patients n = 120,
cardioembolism n = 20), mean levels of tumour necrosis
factor-alpha (TNF-α), interleukin-6 (IL-6) and interleuk-
in-1beta (IL-1β) in patients with ischaemic stroke due to
cardioembolism were significantly higher than in patients
suffering from ischaemic stroke of noncardioembolic ori-
gin.
Aetiological blood biomarkers of cardioembolic strokes
are listed in table 4.
Small vessel disease biomarkers
Aetiological blood biomarkers of SVD stroke are listed in
table 5.
Homocysteine
Homocysteine is an amino acid that is produced via de-
methylation of methionine [73]. Higher levels of homo-
cysteine can lead to endothelial cell injury [74]. Evidence
suggests that homocysteine may further promote fatty de-
posits in blood vessels by damaging the inner lining of ar-
teries and promoting blood clots.
In a case control study [75] with 172 patients suffering
from SVD and 172 healthy controls, mean homocysteine
levels were 1.21 times higher in patients with ischaemic
stroke due to SVC compared with healthy controls (p
<0.0005). However the study did not compare homo-
cysteine levels with other subtypes such as LAA or CE.
Platelet CD40 ligand
After platelet activation, platelet CD40 ligand (CD40L) is
presented on the cell surface. It then binds CD40 on en-
dothelial cells and thereby induces the production of adhe-
sion molecules, inflammatory cytokines and procoagulant
tissue factor [76], all factors with a causal relevance to ath-
erogenesis, most probably also in small vessels [30].
When comparing platelet CD40L expression [32], patients
suffering from small vessel disease (n = 13, mean fluores-
cence intensity: 2.08 ± 0.16) had significantly (p = 0.029)
higher levels compared with patients suffering from cardi-
oembolic ischaemic stroke (n = 17, mean fluorescence in-
tensity: 1.81 ± 0.16), but there was no significant difference
between platelet CD40L in SVD and LAA.
Intercellular adhesion molecule 1
Intercellular adhesion molecule 1 (ICAM1) is a glycopro-
tein expressed on the surface of endothelial cells, macro-
phages and lymphocytes. ICAM1 is induced by IL-1 and
TNF. ICAM 1 is involved in adhesion and transendotheli-
al migration of lymphocytes [77], which may contribute to
small vessel atherosclerosis.
In a cohort study [78], scientists followed up 267 healthy
individuals and compared baseline ICAM1 levels in sub-
jects who developed white matter lesions on MRI with sub-
jects who did not develop white matter lesions after 3 and
6 years. Patients who showed MRI findings of white mat-
ter lesions after 3 years (n = 23, mean ICAM1 levels: 372.6
ng/ml) had 1.19 times higher ICAM1 levels in their blood
compared with patients who had no such findings (n = 219,
mean ICAM1 level: 312.8 ng/ml; p = 0.005).
When comparing MRI findings and ICAM1 levels after 6
years, ICAM1 levels in patients with MRI findings (white
matter lesions, n = 32, mean ICAM1 levels: 347.4 ng/ml)
were still 1.12 times higher in these patients than in healthy
subjects (n = 152, mean ICAM1 levels: 309.0 ng/ml).
Conclusion
The use of rapidly measurable blood biomarkers for aeti-
ological assessment on admission may advance the identi-
fication of patients who need specific secondary preventive
treatment such as oral anticoagulation, and thus accelerate
the onset of optimal secondary prevention, improve patient
outcome and reduce subsequent costs. However, as the re-
search interest in blood biomarkers in the field of stroke ae-
tiology has evolved only over the last few years, most of
the above data on aetiological markers reside still in an ex-
ploratory phase. The studies are rather small and only few
are controlled for potential confounding factors. A new ae-
tiological blood biomarker, before it can be used in clinical
routine, generally needs to provide additional information
to established clinical features. But most of those studies
which have been published so far were very small, did not
include all statistical analyses that have been newly pro-
posed to assess the additive discriminatory value of blood
markers in vascular research, and they mostly involved
post-hoc analyses. There is clearly a need for validation
of these results in larger well-designed studies. Only few
markers were evaluated and validated in rather large, well-
designed studies, and the most promising potential was
shown for the family of the natriuretic peptides in identify-
ing cardioembolic strokes.
To find the ideal marker, the pathological mechanism un-
derlying the stroke should be well understood. In the case
of cardioembolic strokes, biomarkers that have shown as-
sociations with cardiac dysfunction, specifically atrial fib-
rillation, are the most promising. In this case, natriuretic
peptides show a great deal of potential for aetiological rel-
evance. In terms of large artery atherosclerosis, inflam-
matory markers, especially those known to be associated
with carotid atherosclerosis, intima media thickness or in-
tracerebral atherosclerosis, are interesting candidates. LP
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PLA2 seems thus to be an interesting candidate marker, it is
involved in the process of atherosclerosis via hydroxylation
of oxidised phospholipids and thereby starts the process of
attraction of inflammatory cells on the atherosclerotic site.
Currently no marker has yet been identified specifically
for small vessel disease in a large enough stroke cohort,
thus for this aetiological subtype of stroke, further deriva-
tion studies are needed before a marker for further valid-
ation can be recommended. For example, markers reflect-
ing a state of chronic high blood pressure or markers re-
lated to amyloid deposition in small cerebral vessels would
be promising candidates for further evaluation. However,
since there are overlapping pathophysiological mechan-
isms for each aetiology, such as inflammation and thus in-
flammatory markers, it is most likely that panels of blood
biomarkers will be used in the future since no single marker
will be sensitive and specific enough.
Newer studies should provide the answer to the question as
to whether some aetiological biomarkers will help to im-
prove identification of patients for known effective second-
ary prevention treatments after acute ischaemic stroke, and
if patients with abnormal levels of the selected biomark-
ers are at increased risk for recurrent events as a hard and
clinically relevant endpoint. If one or more of the selec-
ted biomarkers are confirmed to be associated with stroke
aetiology and recurrent stroke, interventional studies may
be undertaken to apply in these patients secondary prevent-
ive therapies guided by clinical information and biomarker
Table 4: Aetiological blood biomarkers of cardioembolic strokes.
Blood
biomarker
CE marker
Description Potential clinical Application Study of Reference Size Study Design
Fonseca et al. 2011 [61] 92 patients
(66 ischaemic stroke,
28 CE)
Cohort study
Rodriguez-Yanez et al.
2009 [63]
262 patients, 100 CE Cohort study
Hajsadeghi et al. 2013
[62]
125 patients, 57 CE Cohort study
NTproBNP N-terminal pr-brain natriuretic peptide, vasoactive
peptide hormone, natriuretic and diuretic
properties
Diagnosis of CE in acute
ischaemic stroke
Cojocaru et al. 2009
[60]
163 patients, 81 CE Cohort study
Montaner et al. 2008
[55]
707 patients, 259 CE Cohort study
Yukiiri et al 2008 [59] 131 patients, 62 CE Cohort study
Tamura et al. 2012 [54] 223 patients, 69 CE Cohort Study
Nigro et al. 2014 [56] 342 patients, 144 CE Cohort Study
Zhixin et al. 2013 [58] 142 patients, 36 CE Cohort Study
BNP V Brain natriuretic peptide, vasoactive peptide
hormone, natriuretic and diuretic properties, heart
and brain origin
Diagnosis of CE in acute
ischaemic stroke
Shibazaki et al. 2009
[57]
200 patients, 82 CE Cohort study
Isenegger et al. 2009
[68]
98 patients, 53 CE Cohort study
Montaner et al. 2008
[55]
707 patients, 259 CE Cohort study
D-dimer Fibrin fractions due to plasmin activation, marker
of haemostatic imbalance
Diagnosis of CE in acute
ischaemic stroke
Tombul et al. 2005 [69] 76 patients, 34 CE Cohort study
MRproANP Midregional proatrial natriuretic peptide, secreted
during atrial wall tension stress, natriuretic,
diuretic, vasoactive peptide hormone
Diagnosis of CE in acute
ischaemic stroke
Katan et al. 2010 [67] 362 patients, 131 CE Cohort study
sTM Soluble thrombomodulin, builds complex with
thrombin to activate C-reactive protein
Diagnosis of CE in acute
ischaemic stroke
Dharmasaroja et al.
2012 [71]
93 patients
41 CE
Cohort study
TNF-α Tumour necrosis factor alpha
Inflammatory marker
Diagnosis of CE in acute
ischaemic stroke
Licata et al. 2009 [72] 120 patients, 20 CE Cohort study
IL-6 Interleukin-6, proinflammatory cytokine Diagnosis of CE in acute
ischaemic stroke
Licata G. et al. 2009
[72]
120 patients, 20 CE Cohort study
IL-1β Interleukin-1β, inflammatory marker Diagnosis of CE in acute
ischaemic stroke
Licata G. et al. 2009
[72]
120 patients, 20 CE Cohort study
CE = cardioembolism
Table 5: Aetiological blood biomarkers of small vessel disease (SVD) stroke.
Blood biomarker
SVD Marker
Description Potential clinical
application
Study reference Size Study design
Homocysteine Amino acid, high concentrations linked to
cardiovascular disease
Diagnosis of SVD Hassan et al. 2003 [75] 344 patients, 172 with SVD Cohort study
CD40 ligand on platelet
surface
Expressed on platelets, when bound to
CD40 on endothelial cell activates
procoagulant tissue factor, adhesion
molecules and inflammatory cytokines
Diagnosis of SVD Oberheiden et al. 2012
[32]
51 patients, 13 SVD Cohort study
ICAM1 Intracellular adhesion molecule1,
improves adhesion and transendothelial
migration of lymphocytes
Diagnosis of SVD Markus et al. 2005 [78] 242 patients
23 SVD (3-year follow up)
184 patients
32 SVD (6-year follow up)
Cohort study
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levels. These markers might in the future even serve as sur-
rogate endpoint for new secondary prevention measures.
To specifically address the question on aetiological bio-
markes in acute stroke, the BIOmarker SIGNAture of
Stroke AetioLogy Study (BIOSIGNAL) – a multicenter
international study funded by the Swiss National Science
Foundation (PZ00P3_142422) – was designed and has be-
gun enrolling patients across Europe.
(http://www.research-projects.uzh.ch/p19799.htm ht-
tps://clinicaltrials.gov/ct2/show/
NCT02274727?term=BIOSIGNAL&rank=1)
Funding: Swiss National Science Foundation
(PZ00P3_142422).
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Figures (large format)
Figure 1
Examples of stroke aetiologies (imaging material adapted from Servier Medical Art).
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Figure 2
Most important mechanisms for the formation of cardiac embolism (imaging material adapted from Servier Medical Art).
PFO = patent foramen ovale
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